Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Evaluation of the Influence of Food Regimen on Oshadi D Absorption

This study has been completed.
Information provided by (Responsible Party):
Oshadi Drug Administration Identifier:
First received: March 29, 2011
Last updated: June 20, 2012
Last verified: June 2012
The study will be a non-randomized, open label, single dose, placebo control, single center, and single arm study in healthy subjects. The study will include one administration of placebo and four single administrations of Oshadi D in two different dose levels, administered in two feeding regimen for the evaluation of the influence of food on Oshadi D absorption.

Condition Intervention
Lupus Erythematosus, Systemic
Drug: Oshadi D

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Single Center, Non-randomized, Placebo Controlled Study for the Evaluation of the Influence of Food Regimen on Oshadi D Absorption

Further study details as provided by Oshadi Drug Administration:

Primary Outcome Measures:
  • DNase activity level (Kunitz/mL) for 2 dose levels, and different food regimen [ Time Frame: 24 hours ]

Secondary Outcome Measures:
  • Maximum plasma DNase concentration (ng/mL) in different food regimen and dose levels [ Time Frame: 24 hours ]

Enrollment: 8
Study Start Date: April 2011
Study Completion Date: October 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oshadi D

2 dose levels of Oshadi D in 2 food regimen will be administered as following:

  • Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.
  • On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration
  • On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.
  • On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.
  • On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast.
Drug: Oshadi D
oral administration


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Male/female 21 years old and up.
  • Subject must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
  • Subject must be sterile or infertile or use an approved method of contraception from the time that the first dose of study medication is taken until three months following study completion or discontinuation.

Exclusion Criteria:

  • Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
  • Subject with positive HIV serology or positive HBsAg at screening.
  • History or evidence of any active liver disease.
  • Female subject who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
  • Inability to give written informed consent
  • History of alcohol or drug abuse within 6 months of screening.
  • Subject who have a positive urine drug screen for substances of abuse (benzodiazepine, THC, opiates, amphetamines, cocaine) at the screening.
  • Mental disorders.
  • Subject with poor venous access
  • Significant swallowing disorders
  • Digestive disorders;
  • Small bowel surgery;
  • Mall absorption disorders.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01327352

Assaf Harofe Medical Center,
Zrifin, Israel
Sponsors and Collaborators
Oshadi Drug Administration
Principal Investigator: Keren Duanis, MD Assaf Harofe Medical Center, Israel
Study Director: Hanna Levy, Dr. Oshadi Drug Administration
  More Information

Responsible Party: Oshadi Drug Administration Identifier: NCT01327352     History of Changes
Other Study ID Numbers: OS-DN-P1b-01
Study First Received: March 29, 2011
Last Updated: June 20, 2012

Keywords provided by Oshadi Drug Administration:

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on May 25, 2017